IV busulfan

DRUG2 trials

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc., Assistance Publique - Hôpitaux de Paris

Conditions

Leukemia, MyeloidMultiple Myeloma

Phase 2

IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients

CompletedNCT01009840

Otsuka Pharmaceutical Development & Commercialization, Inc.Multiple Myeloma

Start: 2010-05-31End: 2012-03-31Updated: 2014-09-25

Reduced Toxicity Conditioning Prior to Unrelated Cord Cell Transplantation for High Risk Myeloid Malignancies

Assistance Publique - Hôpitaux de ParisLeukemia, Myeloid

Start: 2015-05-31End: 2019-05-31Updated: 2018-08-13